Rodrigo Erlich1,3, Cecile Rose T. Vibat2 and Veena M. Singh2*
1Bay Hematology/Oncology, 8221 Teal Drive, Suite 302, Easton, MD, USA
2Biocept, Inc., 5810 Nancy Ridge Drive, San Diego, CA, USA
3Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA
Introduction: Tumor molecular profiling is key for personalized medicine strategies to manage disease in cancer patients. Liquid biopsy can sensitively evaluate biomarker status without the complications and costs associated with surgical biopsies, particularly for patients unable or unwilling to undergo invasive procedures.Materials and
Methods: Patient blood was collected for liquid biopsy testing by Biocept’s CLIA-certified, CAP-accredited laboratory. Dual CTC and ctDNA platforms were utilized to detect EGFRmutations in ctDNA and ALK or ROS1 gene rearrangements by FISH in CTCs.Results and
Discussion: Described are three metastatic NSCLC patients where liquid biopsy results guided targeted therapy selections when standard tissue biopsy was inadequate to assess biomarker status. For all three patients, EGFR TKI treatment was prescribed upon detecting an activating EGFRmutation by liquid biopsy. One patient exhibited complete response for approximately two years. Two patients received osimertinib following emergence of the EGFR T790M resistance mutation detected by liquid biopsy.Conclusion: Liquid biopsy analyses of ctDNA and CTCs in blood can complement tumor testing, providing information on drivers related to a patient’s cancer. Clinical utility of liquid biopsy is demonstrated where first line and subsequent targeted treatment was prescribed upon identifying genomic alterations found in blood, and the patients received therapeutic benefit that significantly extended survival and enhanced their quality of life.
Erlich R, Vibat CRT, Singh VM. Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC Patients. Clin Oncol. 2019; 4: 1567.